Institution
Tufts Center for the Study of Drug Development
About: Tufts Center for the Study of Drug Development is a based out in . It is known for research contribution in the topics: Drug development & Clinical trial. The organization has 78 authors who have published 258 publications receiving 16047 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is found that fast track candidates were widely diverse in characteristics and development histories, and estimates of the program's value should include assessment of the resulting marketed products.
Abstract: The U.S. Food and Drug Administration's (FDA) Fast Track program, created in 1997, was designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Although the intent is laudable, the significance of designations and effectiveness of the program have recently come into question. Tufts Center for the Study of Drug Development has collected data on fast track candidates since 1998. We analyzed the current dataset of 344 fast track candidates granted nearly 400 designations, representing approximately 70% of the fast track designations granted by FDA, to address questions regarding common metrics. We found that fast track candidates were widely diverse in characteristics and development histories. The complexity and limitations of the data introduced biases in metrics such as clinical phase lengths and phase transition probabilities, although these could be determined for subsets of the candidates. Our results suggest that evaluation of the Fast Track program requires a nuanced approach, and estimates of the program's value should include assessment of the resulting marketed products.
9 citations
••
TL;DR: The success of the EU in meeting the timeline goals for the group and for separate categories of biopharmaceuticals (recombinant proteins, monoclonal antibodies, and antisense oligonucleotides) is documents.
9 citations
••
TL;DR: The diagnostic algorithm (nNO/HSVM+TEM) with parallel testing outperforms algorithms with tests in sequence and can inform the dialogue on the development of evidence-based guidelines for PCD diagnostic testing.
Abstract: Primary Ciliary Dyskinesia (PCD) diagnosis relies on a combination of tests which may include (a) nasal Nitric Oxide (nNO), (b) High Speed Video Microscopy (HSVM) and (c) Transmission Electron Microscopy (TEM). There is variability in the availability of these tests and lack of universal agreement whether diagnostic tests should be performed in sequence or in parallel. We assessed three combinations of tests for PCD diagnosis and estimated net sensitivity and specificity as well as cost-effectiveness (CE) and incremental cost-effectiveness (ICE) ratios. A hypothetical initial population of 1000 referrals (expected 320 PCD patients) was followed through a probabilistic decision analysis model which was created to assess the CE of three diagnostic algorithms (a) nNO + TEM in sequence, (b) nNO + HSVM in sequence and (c) nNO/HSVM in parallel followed, in cases with conflicting results, by confirmatory TEM (nNO/HSVM+TEM). Number of PCD patients identified, CE and ICE ratios were calculated using Monte Carlo simulations. Out of 320 expected PCD patients, 313 were identified by nNO/HSVM+TEM, 274 with nNO + HSVM and 198 with nNO + TEM. The nNO/HSVM+TEM had the highest mean annual cost (€209 K) followed by nNO + TEM (€150 K) and nNO + HSVM (€136 K). The nNO + HSVM algorithm dominated the nNO + TEM algorithm (less costly and more effective). The ICE ratio for nNO/HSVM+TEM was €2.1 K per additional PCD patient identified. The diagnostic algorithm (nNO/HSVM+TEM) with parallel testing outperforms algorithms with tests in sequence. These findings, can inform the dialogue on the development of evidence-based guidelines for PCD diagnostic testing. Future research in understudied aspects of the disease, such as PCD-related quality of life and PCD-associated costs, is needed to help the better implementation of these guidelines across various healthcare systems.
8 citations
••
TL;DR: The regulation of foods and drugs in the United States has repeatedly been increased in response to unjustified marketing claims or instances of dramatic harm from these substances.
8 citations
••
TL;DR: This commentary examines the development, regulatory, and reimbursement challenges facing abuse-deterrent formulation (ADF) products and suggests more clarity is needed from regulatory authorities regarding standards for proving ADF labeling claims and data exclusivity eligibility.
8 citations
Authors
Showing all 78 results
Name | H-index | Papers | Citations |
---|---|---|---|
Henry G. Grabowski | 44 | 117 | 12868 |
Janice M. Reichert | 44 | 94 | 9253 |
Jeffrey S. Brown | 42 | 161 | 6312 |
Toben F. Nelson | 40 | 136 | 9539 |
Francisco J. de Abajo | 33 | 97 | 4181 |
Joseph A. DiMasi | 31 | 76 | 11513 |
Kenneth I. Kaitin | 28 | 92 | 2518 |
Kenneth A. Getz | 20 | 97 | 2428 |
Joshua Cohen | 19 | 63 | 927 |
Andrew W. Wilson | 18 | 40 | 2977 |
Christopher-Paul Milne | 13 | 44 | 494 |
Michael Manocchia | 12 | 17 | 1090 |
Ronald P. Evens | 11 | 21 | 312 |
Cherie Paquette | 11 | 32 | 627 |
Stella Stergiopoulos | 9 | 18 | 211 |